{
  "ticker": "LLY",
  "target_date": "2025-01-02",
  "actual_date": "2025-01-02",
  "collected_at": "2025-12-08T11:13:41.160753",
  "price": {
    "open": 774.81,
    "high": 781.17,
    "low": 766.06,
    "close": 772.3094482421875,
    "volume": 1938900,
    "change_1d_pct": 0.79,
    "change_7d_pct": 1.34,
    "change_30d_pct": 7.0
  },
  "technicals": {
    "rsi_14": 42.59,
    "sma_20": 783.83,
    "sma_50": 796.5,
    "macd": -6.846,
    "macd_signal": -7.434,
    "macd_histogram": 0.589,
    "bb_upper": 824.25,
    "bb_lower": 743.42,
    "price_vs_sma20_pct": -1.47,
    "price_vs_sma50_pct": -3.04,
    "volume_ratio": 0.61
  },
  "fundamentals": {
    "market_cap": 891907211264,
    "pe_ratio": 48.746937,
    "forward_pe": 43.906662,
    "price_to_book": 37.459526,
    "price_to_sales": 15.010269,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.53,
    "pct_from_52w_low": 59.5
  },
  "macro": {
    "spy": {
      "price": 579.56,
      "change_1d_pct": -0.25,
      "change_7d_pct": -1.69
    },
    "vix": {
      "level": 17.93,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.57
    },
    "dollar_index": {
      "level": 109.39
    },
    "gold": {
      "price": 2658.9
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "source": "MarketWatch",
      "datetime": 1735835580,
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=6fb7a7605ba70cebb835d00b4051b34da1fb4a4b08e8fd2015a7f1d1d3c1b205"
    },
    {
      "headline": "Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst",
      "source": "Yahoo",
      "datetime": 1735833900,
      "summary": "According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly\u2019s business strategy, means Zepbound is set to overtake competitors.",
      "url": "https://finnhub.io/api/news?id=e2ca9bd82ac09b26edfda8f132dcd6094c27d763c07ace0812903fa9facd8435"
    },
    {
      "headline": "Eli Lilly Stock Upgraded to \"Buy\" as Analysts Boost Price Target to $1,250",
      "source": "Yahoo",
      "datetime": 1735830414,
      "summary": "Eli Lilly's Strong Pipeline and Earnings Lead to Stock Upgrade and Higher Price Target",
      "url": "https://finnhub.io/api/news?id=1147bbe66e946a6b89412eb1c2b36fc0692333c2255b1c18359121a77fa341d1"
    },
    {
      "headline": "US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report",
      "source": "Yahoo",
      "datetime": 1735827620,
      "summary": "Eli Lilly and Co.'s (NYSE:LLY) Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) Wegovy (semaglutide) for market dominance. According to a GlobalData report, Zepbound's superior effectiveness and strategic market growth posit",
      "url": "https://finnhub.io/api/news?id=6f17fc6ed29c9b2abaa786d74436d743a10e06357b73844515fd84095fddde65"
    },
    {
      "headline": "5 Large Drug Stocks to Keep An Eye On in the New Year",
      "source": "Yahoo",
      "datetime": 1735825260,
      "summary": "R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio.",
      "url": "https://finnhub.io/api/news?id=5c4e85b9cdfce8579155e19b652e5590cfd40b26b8a07a3e0ca3dfb27a46213a"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470584.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000291/xslF345X05/wk-form4_1734470584.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470498.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000289/xslF345X05/wk-form4_1734470498.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470366.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000287/xslF345X05/wk-form4_1734470366.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470270.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000285/xslF345X05/wk-form4_1734470270.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470180.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000283/xslF345X05/wk-form4_1734470180.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}